Literature DB >> 29093349

Riboflavin Transporters RFVT/SLC52A Mediate Translocation of Riboflavin, Rather than FMN or FAD, across Plasma Membrane.

Congyun Jin1, Yoshiaki Yao1, Atsushi Yonezawa1, Satoshi Imai1, Hiroki Yoshimatsu1, Yuki Otani1, Tomohiro Omura1, Shunsaku Nakagawa1, Takayuki Nakagawa1, Kazuo Matsubara1.   

Abstract

Riboflavin (vitamin B2) plays a role in various biochemical oxidation-reduction reactions. Flavin mononucleotide (FMN) and FAD, the biologically active forms, are made from riboflavin. Riboflavin transporters (RFVTs), RFVT1-3/Slc52a1-3, have been identified. However, the roles of human (h)RFVTs in FMN and FAD homeostasis have not yet been fully clarified. In this study, we assessed the contribution of each hRFVT to riboflavin, FMN and FAD uptake and efflux using in vitro studies. The transfection of hRFVTs increased cellular riboflavin concentrations. The uptake of riboflavin by human embryonic kidney cells transfected with hRFVTs was significantly increased, and the efflux was accelerated in a time-dependent manner. However, the uptake and efflux of FMN and FAD hardly changed. These results strongly suggest that riboflavin, rather than FMN or FAD, passes through plasma membranes via hRFVTs. Our findings could suggest that hRFVTs are involved in riboflavin homeostasis in the cells, and that FMN and FAD concentrations are regulated by riboflavin kinase and FAD synthase.

Entities:  

Keywords:  FAD; flavin mononucleotide; riboflavin; transporter; vitamin B2

Mesh:

Substances:

Year:  2017        PMID: 29093349     DOI: 10.1248/bpb.b17-00292

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

Review 1.  Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.

Authors:  Shaowei Zhang; Mary E W Collier; Derren J Heyes; Flaviano Giorgini; Nigel S Scrutton
Journal:  Arch Biochem Biophys       Date:  2020-12-01       Impact factor: 4.013

Review 2.  Development of Novel Experimental Models to Study Flavoproteome Alterations in Human Neuromuscular Diseases: The Effect of Rf Therapy.

Authors:  Maria Tolomeo; Alessia Nisco; Piero Leone; Maria Barile
Journal:  Int J Mol Sci       Date:  2020-07-26       Impact factor: 5.923

3.  Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics.

Authors:  Lisa Bartmann; David Schumacher; Saskia von Stillfried; Marieke Sternkopf; Setareh Alampour-Rajabi; Marc A M J van Zandvoort; Fabian Kiessling; Zhuojun Wu
Journal:  Front Pharmacol       Date:  2019-02-06       Impact factor: 5.810

4.  Chemical Constituents and Molecular Mechanism of the Yellow Phenotype of Yellow Mushroom (Floccularia luteovirens).

Authors:  Xiaolong Gan; Xuemei Bao; Baolong Liu; Yun Li; Dong Cao; Hg Zhang; Yuan Zong
Journal:  J Fungi (Basel)       Date:  2022-03-18

5.  Effect of riboflavin deficiency on development of the cerebral cortex in Slc52a3 knockout mice.

Authors:  Congyun Jin; Atsushi Yonezawa; Hiroki Yoshimatsu; Satoshi Imai; Madoka Koyanagi; Kaori Yamanishi; Shunsaku Nakagawa; Kotaro Itohara; Tomohiro Omura; Takayuki Nakagawa; Junya Nagai; Kazuo Matsubara
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.